MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/rmdopen-2023-003890

Медицинская библиотека · RMD open · 2024

Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry.

Kuemmerle-Deschner Jasmin B, Kallinich Tilmann, Henes Joerg, Kortus-Götze Birgit, Oommen Prasad T, Rech Juergen, Krickau Tobias, Weller-Heinemann Frank, Horneff Gerd, Janda Aleš, Foeldvari Ivan, Schuetz Catharina, Dressler Frank, Borte Michael, Hufnagel Markus, Meier Florian, Fiene Michael, Andreica Ioana, Weber-Arden Julia, Blank Norbert

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Interim analysis of the RELIANCE registry, an on-going, non-interventional, open-label, multicentre, prospective study evaluating the long-term safety, dosing regimens and effectiveness of canakinumab in patients with cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), tumour-necrosis factor receptor-associated periodic syndrome (TRAPS) or mevalonate-kinase deficiency (MKD)/hyperimmunoglobulin-D syndrome (HIDS).

METHODS

From September 2017 for patients with CAPS, and June 2018 for patients with FMF, TRAPS or MKD/HIDS, the registry enrolled paediatric (aged ≥2 years) and adult patients (aged ≥18 years) receiving canakinumab as part of their routine medical care. Safety, canakinumab dose, disease activity and quality of life outcome measures were evaluated at baseline and every 6 months until end of study visit.

RESULTS

At the analysis cut-off date (December 2020), 168 patients (91 CAPS, 54 FMF, 16 TRAPS and 7 MKD/HIDS) were enrolled. 85 (50.9%) patients were female and 72 (43.1%) were children (<18 years). The median patient age was 20.0 years (range 2.0-79.0 years). In the CAPS cohort, serious infections and serious adverse drug-reactions were more common in patients receiving higher than the recommended starting dose (SD) of canakinumab. A trend to receive >SD of canakinumab was observed in the pooled population. The majority of patients were reported as having either absent or mild/moderate disease activity (physician's global assessment) from baseline to Month 30, with a stable proportion of patients (~70%) in remission under canakinumab treatment. Patient-reported disease activity (Visual Analogue Scale (VAS), Autoinflammatory Disease Activity Index), fatigue (VAS); markers of inflammation (C-reactive protein, serum amyloid A and erythrocyte sedimentation rate) remained well-controlled throughout.

CONCLUSION

Data from this analysis confirm the long-term safety and effectiveness of canakinumab for the treatment of CAPS, FMF, TRAPS and MKD/HIDS.

Для цитирования: Kuemmerle-Deschner Jasmin B, Kallinich Tilmann, Henes Joerg, Kortus-Götze Birgit, Oommen Prasad T, Rech Juergen, Krickau Tobias, Weller-Heinemann Frank, Horneff Gerd, Janda Aleš, Foeldvari Ivan, Schuetz Catharina, Dressler Frank, Borte Michael, Hufnagel Markus, Meier Florian, Fiene Michael, Andreica Ioana, Weber-Arden Julia, Blank Norbert. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry.. RMD open. 2024. DOI: 10.1136/rmdopen-2023-003890.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.